Plain-English translation of NCT07585760 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether CM336 combined with isatuximab can help patients newly diagnosed with multiple myeloma—a blood cancer—who also have severe kidney damage. Both medications are antibodies designed to attack the cancer cells in a new way. The study will enroll 20 patients and follow them through three cycles of treatment.
Multiple myeloma patients with severe kidney damage are harder to treat because their kidneys struggle to process traditional cancer drugs. This trial exists to see if these two newer antibody medications might work better and be safer for this vulnerable group of patients.
You likely qualify if…
You likely don't qualify if…
You will receive three cycles of treatment with the two antibody medications, likely given by injection or infusion at the hospital. Each cycle will involve regular clinic visits where doctors will monitor how you're responding and check your kidney function, blood counts, and overall health. The exact schedule will be explained when you enroll, but you should expect frequent appointments during the three treatment cycles.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China